	臺 中 榮 民 總 醫 院 Taichung Veterans General Hospital	
	管制文件訂修廢紀錄表 Record of Composition and Revisions of Controlled Documents	
文件編號 Document Number	IRB-本會-工作常規-2026 文件名稱 臨床研究利益衝突審議及處 IRB-Regulations of Operation-2026 Title SOP for Handling O Interest in Clinical	onflict of
訂定單位 Composed by	The IRB Committees Level of Confidentiality	極機密 ghly confidential
適用單位 Applied to	■其他,請註明:人體研究倫理審查委員會 ■Other (Please specify): The IRB Committees	
版次 頁數	文件修訂摘要	實施日期
Version No. Page A 17	Summary of Revisions of the Document 新訂。	Date of Implementation 20190527
''	Newly composed.	20130327
B 18	1. 依據 AAHRPP 國際認證委員之建議進行增修。	
	 The following modifications were made according to the recommendations of AAHRPP (Association for the Accreditation of Human Research Protection Program) reviewers. 新增 5.2.1.3: 若有財務利益狀況/非財務關係之改變時(自新取得 財務利益之日起回溯 12 個月之財務利益總和達顯著利益門檻、 或新增研究人員等)應於 30 日內更新申報資料。 Added Item 5.2.1.3: In the event of a change in the financial interest/non-financial relationship (the sum of the financial benefits over the last 12 months reaches the significant interest threshold calculating from the first day of acquiring new financial benefits or the addition of researchers etc), the related report of the proposal should be updated and sent to the IRB within 30 days. 新增 5.4.4: 人體研究倫理審查委員會參考利益衝突審議小組之決 議,決定是否通過試驗/研究計畫/核准試驗/研究計畫繼續執行,並 確認是否符合試驗/研究委託機構以及主管機關的通報規定。 Added Item 5.4.4: Based on the resolution made by the conflict of interest review taskforce, the IRB decides whether to pass the trial/study protocol or approve trial/study protocol to be continued, and verify whether it complies with the reporting requirements defined by the sponsor and competent authority. 	/

	臺 中 榮 民 總 醫 院 Taichung Veterans General Hospital	
	管制文件訂修廢紀錄表 Record of Composition and Revisions of Controlled Documents	
文件編號 Document Number	IRB-本會-工作常規-2026 文件名稱 臨床研究利益衝突審議及處 IRB-Regulations of Operation-2026 文件名稱 SOP for Handling C Interest in Clinica Interest in Clinica	onflict of
訂定單位 Composed by	人體研究倫理審查委員會 The IRB Committees 機密等級 Level of Confidentiality Unclassified □confidential □hig	極機密
適用單位 Applied to	□全院 □All units in the hospital ■其他,請註明:人體研究倫理審查委員會 ■Other (Please specify): The IRB Committees	
版次 頁數	文件修訂摘要	實施日期
Version No. Pages B 18	Summary of Revisions of the Document 4. 修改 5.5.5.2 為研究人員未配合財務利益衝突的政策	Date of Implementation 20191018
	 和程序。 4. Revised 5.5.5.2: Research personnel shall be educated about conflict of interest policy or procedure when they do not comply with related policies and procedures. 5. 修改 5.5.5 標題為「需立即進行教育訓練(educational training)的情況」 5. Revised the title of Item 5.5.5: Educational training is required immediately when: 1. 修改參考文件 3.2 為「藥品優良臨床試驗作業準則」109 年 08 月 28 日衛生福利部部授食字第 1091407788 號令修正。 1. Updated reference 3.2 into ""Regulations for Good Clinical Practice" amended on August 28 2020, pursuant to Ministry of Health and Welfare Bu-Shou-Shi-Zi No. 1091407788." 2. 文字校正。 2. Fixed typos. 3. 原 5.3.3 內容修改為 5.4.2。 3. Item 5.3.3 was moved to item 5.4.2. 4. 修改原 5.4.2 標號為 5.4.3。 4. Changed the original item number 5.4.2 to 5.4.3. 	

	Taicoute degrans General	臺 中 Taichun	y 榮 戶 g Veterans			院 nital	
	管制] 文 件	- 訂修	廢約	已錄	表	
文件編號 Document Number	IRB-本會-二	of Composition 工作常規-2026 s of Operation-202		爯 路床研究 SOF	記利益衝穿 P for Ha	突審議及處	置管理程序書 conflict of I Study
訂定單位 Composed by	The IRB	理審查委員會 Committees		及 ■普通		产件 🗌	極機密 ghly confidential
適用單位 Applied to	■其他,言		ital 體研究倫理 fy): The IRB				
版次 頁數		_	文件修訂摘				實施日期
Version No. Pages D 18	· . 更改文	Summary of	f Revisions o	of the Docu	ument		Date of Implementation 20230717
	 The o was readed as the o was readed as the readed as the readed as the readed as the organized as the organize	inginal "Thenamed "Thenamed "Thenamed "Thenamed "Thenamed "Thenamed "Thenamed" "Thenamed" "Thenamed" "Thenamed" "Thenamed" "Thenamed" and interest of the second structures and	em 5.4.4 wa 突審議小組 情況,將提 The Conf regularly onflict of e Human ere is a conf 5.7。 ginal item nu	cond IRB mittees". 之建議ad Were mad AHRPP (A n Resear as modifie 解究 體 和 制 和 制 和 制 相 明 相 明 相 明 相 明 相 明 相 明 相 明 相 明 相 明 相	Comi 行 acco Associa cch Pro ed. 受資倫 erest I infor h Pro erest, it	mittees" ording to ation for otection 者,審 Review annual mation tection will be	^{臺中樂民} 2023.0 參考了
訂修 Composed/Rev			審核 Reviewe	d			核准 proved
※管制 文体 ※本文件以 ※Changing ,	本文 壽檀 《M系統為 marking, or	收 及做<mark>把</mark>就到 最新版本,約 copying cont	權責主 權責主 (本發行需經 in the Knowle	管正式 SOP管理中 ents withou	<mark>P 管</mark> ′心核章 t permis	准, 理中 , ^{嚴禁自}	行列印。 ohibited.

Changing, marking, or copying controlled documents without permission is prohibited.
 The latest version of this document in the Knowledge Management System (KMS) takes precedence. Distribution of hard copies of this document must be approved and stamped by the SOP Administrative Center. Copying without permission is strictly prohibited.

臺中榮民總醫院 Taichung Veterans General Hospital		
管制文件訂修廢會審單		
Review Form of Composition and Revisions of Controlled Documents	空空的一个	
文件編號 IRB-本會-工作常規-2026 文件名稱 臨床研究利益衝突審議及處 Document Number IRB-Pagulations of Operation-2026 Title SOP for Handling Conflic		
Clinical Stud	dy	
會辦單位 審查意見 Processing Unit Review Comments	會辦單位主管 Head of Processing Unit	
	nead of Flocessing onic	
There is no need for review by other departments or divisions.		
	臺中榮民總醫	醫院
	2023.08.	3.10
	參考文件	件
·*: 請久會辦單位主管車腸案查音目後核音,必要時得直接與訂定問題。		

※請各會辦單位主管惠賜審查意見後核章,必要時得直接與訂定單位協商。

%The head of each processing unit is advised to provide comments before signing/stamping to approve. If needed, it is recommended that the head of each processing unit discuss with the unit that made the SOP.

	Taichung Georgens Georgens	臺 Taichı	中 榮 ung Vetera	民 ans G	總 ienera	殿 西 I Hos	院 pital		
文件編號	IRB-本會-工作常規-2026		臨床研究利益					頁次 Page	1/18
	IRB-Regulations of Operation-2026	名稱 Title			ling Co Clinical			版次 Version	D版
			•					••	

1.目的

臺中榮民總醫院(以下簡稱本院)為規範臨床試驗/研究相關之財務利 益衝突審議程序、認定標準及處置辦法,以確保研究的客觀公正與落 實受試(訪、檢)者的保護機制,特制訂本管理程序書。

1. Purpose

The purpose of this SOP is to provide guidance for reviewing, identifying, and handling conflict of interest in clinical studies at Taichung Veterans General Hospital, so as to ensure objective and fair research and to implement subject protection mechanism.

2.適用範圍

此管理程序書適用於所有臨床試驗/研究之審查,無論臨床試驗/研究 經費的來源皆採一致標準,以避免因利益衝突,而影響對受試(訪、 檢)者權益之保護。

2. Scope

This SOP applies to the review of all clinical studies; same review standards shall be adopted for all studies regardless of the source of funding to ensure that the protection of the subjects' rights and welfare is not affected by conflict of interest.

023

08.10

- 3.参考文件
- 3. References
 - 3.1「人體研究法」總統華總一義字第 10000291401 號令制定公布 全文 26 條,民國 100 年 12 月 28 日施行。
 - 3.1 Human Subjects Research Act, promulgated as per the Presidential Order Hua-Zong-Yi-Yi-Zi No. 10000291401 dated 28 December 2011.
 - 3.2「藥品優良臨床試驗作業準則」109年08月28日衛生福利部部 授食字第1091407788號令修正。
 - 3.2 "Regulations for Good Clinical Practice" amended on August 28 2020, pursuant to Ministry of Health and Welfare Bu-Shou-Shi-Zi No. 1091407788.



文件編號 IRB-本會-工作常規-2026

Document Number | IRB-Regulations of Operation-2026

文件 臨床研究利益衝突審議及處置管理程序書 名稱 SOP for Handling Conflict of

中榮民總

Interest in Clinical Study

賢西

院

頁次 2/18Page 版次 D 版 Version

民總醫院

.08.1

3.3 「人體試驗管理辦法」105 年 4 月 14 日衛生福利部衛部醫字第 1051662154 號令修正。

Title


- 3.3 Regulations on Human Trials, promulgated by the Ministry of Health and Welfare, amended on 14 April 2015, pursuant to Wei-Bu-Yi-Zi No. 1051662154.
- 3.4 AAHRPP Element I.6.B. The Organization has and follows written policies and procedures to identify, manage, and minimize or eliminate individual financial conflicts of interest of Researchers and Research Staff that could influence the conduct of the research or the integrity of the Human Research Protection Program. The Organization works with the Institutional Review Board or Ethics Committee in ensuring that financial conflicts of interest are managed and minimized or eliminated, when appropriate.
- 4.名詞定義
- 4. Definitions
 - 4.1 財務利益(Financial Interest)

指具貨幣價值之任何項目,包括但不限於,勞務款項(例如,顧 問費、演講費、鐘點費、出席費、服務收入或類似費用、與臨床 試驗/研究相關且可能受試驗/研究結果所影響的金錢補助等)、 股權(例如,股票、認股權或其他與試驗/研究相關且可能受研 究結果所影響的所有權利益),以及智慧財產權(例如,專利、 著作權和該等權利之權利金),下列各款不屬於前條所稱財務 利益:

4.1 Financial Interest

Financial interest refers to any items of monetary value, including but not limited to, labor service payment (e.g. consulting fees, honoraria for speakers, hourly wages, attendance fees, service revenue or similar expenses, and stipends related to the study and potentially affected by the study result), equity (e.g. stock, stock options, or titles related to the study and potentially affected by the study result), and

	Taiching General General		そ 民 總 terans Genera	- •		
文件編號	[IRB-本會-工作常規-2026]文件 臨床研究利益衝突審議及處置管理程序				頁次 Page	3/18
Document Number	IRB-Regulations of Operation-2026		erest in Clinica		版次 Version	D版
	intellectual prope thereof), exclusiv		÷ ·	pyright, an	d royal	ty
	4.1.1 由臨床試驗/A 因執行臨床言 合理費用。		付給本院,再 ,且臨床試験			
	-	ion of the stu	able expense dy paid by the dividuals invo	sponsor to	o TCVG	
	4.1.2 持有共同基金	•				
	4.1.2 Mutual fund	holdings				
		義,且與該臨,	舉辦之學術活 末試驗/研究計 、服務收入或	畫不相關,		
	academic ao similar mee	enue or simil ctivities, com etings orgar	hourly wage ar expenses mittees, expenses nized by pu ed to the stud	for partici ert groups ıblic or r	pating or oth	in er
4.2	2 個人之顯著則 Interest):指下列		Individual S	ignificant	Financi	al
4.2	2 Individual Signifi following circums		al Interest, ref	ferring to a	ny of th	ne
		委託者及其相	成年子女自臨, 關的實體所收, 台幣 150,000	受之款項總	額,於	過
	NT\$150,000	dent childre (approxima the paymen	ch team mem n have rec tely US\$5,00 t of a single s	ceived mo 0) in the	ore that past 2	an 12





transfer of technology.

- 4.3.3 本院醫療、醫事及研究部門之一級(含)以上主管,為該臨床 試驗/研究計畫所使用之專利或著作之所有權人或獲有智慧 財產權授權金。
- 4.3.3 The chair or director of a TCVGH first-level medical, administrative or research department is the owner of the patent or work used in the study, or receives IPR license fees.

榮民總醫院

3.08.1

- 4.3.4 本院醫療、醫事及研究部門之一級(含)以上主管與其配偶以及未成年子女自單一試驗/研究委託者及其相關的實體所收受之款項總額,於過去 12 個月期間,超過新臺幣 150,000元。
- 4.3.4 The chair or director of a TCVGH first-level medical, administrative or research department, his/her spouse and dependent children have received payment of more than NT\$150,000 from a single sponsor of the study and related entities in the past 12 months.
- 4.3.5本院醫療、醫事及研究部門之一級(含)以上主管與其配偶以及未成年子女自單一試驗/研究委託者及其相關的實體之股權總額,符合下列任一條件:參考公開價格、或其他公平市場價值之合理衡量認定下,價值超過新臺幣150,000元;或所代表任何單一實體之所有股權超過5%。
- 4.3.5 The chair or director of a TCVGH first-level medical, administrative or research department, his/her spouse and dependent children have received more than NT\$150,000 worth of equities or more than 5% of the total equities held by any entity they represent from a single sponsor of the study and related entities; the value of the equities shall be determined by referencing public market values or any other fair market values.
- 4.4 利益衝突(Conflict of Interest; COI): 指個人利益/次要利益導引專業判斷或行動,會對受試者權益/主 要利益造成不當影響而產生風險。例如計畫主持人/研究人員/審



查委員有個人利益/次要利益,可能影響其研究執行或研究審查 的客觀公正性,導致產生對受試者權益/主要利益或安全不當之 影響。

4.4 Conflict of Interest (COI):

"Conflict of Interest; COI" refers to situations in which personal secondary interests interests or may compromise а researcher's professional judgment or behavior and may cause a negative impact or risk to the subjects' rights or primary For example, a situation in which the principal interests. investigator, research team member, or reviewer has personal or secondary interests may affect the objectivity or impartiality of the conduct or review of the research, which may lead to a negative impact on the subjects' rights, primary interests, or safety.

専由祭民

IND=本曾=工作市税:2020 名稱 Title cument Number IRB-Regulations of Operation-2026 名稱 Title 5.作業內容 5. Procedure 5.1 人體研究倫理審查委員 5.1 月ow Chart of the Secclinical Study 1 「中報顯著之財務利益 /非財務關係 計畫 同主 Pl/ R 承辦 員/(Staf (M 五衝突審議小組審 重 利益衝突審議小組審 重 6 「利益衝突審議小組審 重 7 「利益衝突審議小組審 重 7 「利益衝突處置及」 7	SOP for I Interes 會臨床研究 OP for Ha 權責 nsible Personne 主持人/共(協) 持人/研究人員 Co-I/Sub-I/ esearcher 人員/審查委) 顯著財務利益暨非財務關係申報表 Statement of Disclosure of Significant Financial Interests and Non-financial Relationships 顯著財務利益暨非財務關係申報表
Ittle Title 5.作業內容 5. Procedure 5.1 人體研究倫理審查委員 5.1 Flow Chart of the Standard Study 流程 Flow Chart 中報顯著之財務利益 /非財務關係 利益衝突審議小組審 人 東ノ利益衝突處置及	Interes 會臨床研究 OP for Ha 權責 nsible Personne 主持人/共(協) 持人/研究人員 Co-I/Sub-I/ esearcher 人員/審查委	成火 Version D 版 E利益衝突審議及處置流程圖 1 Indling Conflict of Interest in Relevant Documents 2023 顧著財務利益暨非財務關係申報表 Statement of Disclosure of Significant Financial Interests and Non-financial Relationships 顯著財務利益暨非財務關係申報表 2023
5. Procedure 5.1 人體研究倫理審查委員 5.1 Flow Chart of the Se <u>Clinical Study</u> <u>流程</u> Flow Chart Respond 市畫 月主 月/ R 新畫 月主 月/ R 承辦 員/(Staf (利益衝突審議小組審 重 」 和益衝突審議小組審	DP for Ha 權責 hsible Personne 主持人/共(協) 持人/研究人員 Co-I/Sub-I/ esearcher 人員/審查委	ndling Conflict of Interest in 相關文件 el Relevant Documents) 顯著財務利益暨非財務關係申報表 Statement of Disclosure of Significant Financial Interests and Non-financial Relationships 顯著財務利益暨非財務關係申報表
5.1 人體研究倫理審查委員 5.1 Flow Chart of the Section	DP for Ha 權責 hsible Personne 主持人/共(協) 持人/研究人員 Co-I/Sub-I/ esearcher 人員/審查委	ndling Conflict of Interest in 相關文件 el Relevant Documents) 顯著財務利益暨非財務關係申報表 Statement of Disclosure of Significant Financial Interests and Non-financial Relationships 顯著財務利益暨非財務關係申報表
5.1 Flow Chart of the Se Clinical Study 流程 Flow Chart Respon 中報顯著之財務利益 /非財務關係 利益衝突之評估 和益衝突審議小組審 直 利益衝突審議小組審 藍測利益衝突處置及	DP for Ha 權責 hsible Personne 主持人/共(協) 持人/研究人員 Co-I/Sub-I/ esearcher 人員/審查委	ndling Conflict of Interest in 相關文件 el Relevant Documents) 顯著財務利益暨非財務關係申報表 Statement of Disclosure of Significant Financial Interests and Non-financial Relationships 顯著財務利益暨非財務關係申報表
Clinical Study 流程 Flow Chart Response 申報顯著之財務利益 計畫 /非財務關係 計畫 利益衝突之評估 無 利益衝突を誘張小組審 // 利益衝突審議小組審 // 直 利益衝突處置及	權責 nsible Personne 主持人/共(協) 持人/研究人員 Co-I/Sub-I/ esearcher 人員/審查委	相關文件 el Relevant Documents) 顯著財務利益暨非財務關係申報表 Statement of Disclosure of Significant Financial Interests and Non-financial Relationships 顯著財務利益暨非財務關係申報表
Flow Chart Responsibility 甲報顯著之財務利益 計畫 /非財務關係 日主 /非財務關係 月/(利益衝突之評估 無 利益衝突審議小組審 //(利益衝突審議小組審 //(動益衝突處置及 利益	nsible Personne 主持人/共(協) 持人/研究人員 Co-I/Sub-I/ esearcher 人員/審查委	el Relevant Documents) 顯著財務利益暨非財務關係申報表 Statement of Disclosure of Significant Financial Interests and Non-financial Relationships 顯著財務利益暨非財務關係申報表
 申報顯著之財務利益 /非財務關係 /非財務關係 月/(不辨 利益衝突之評估 利益衝突審議小組審 査 1 「利益衝突審議小組審 査 「利益衝突處置及 「利益衝突處置及 「利益衝突處置及 「利益 「日主 「日三 「日 「日<!--</td--><td>主持人/共(協) 持人/研究人員 Co-I/Sub-I/ esearcher 人員/審查委</td><td>) 顯著財務利益暨非財務關係申報表 Statement of Disclosure of Significant Financial Interests and Non-financial Relationships 顯著財務利益暨非財務關係申報表 </td>	主持人/共(協) 持人/研究人員 Co-I/Sub-I/ esearcher 人員/審查委) 顯著財務利益暨非財務關係申報表 Statement of Disclosure of Significant Financial Interests and Non-financial Relationships 顯著財務利益暨非財務關係申報表
 申報顯著之財務利益 /非財務關係 月上 PI/ R 承辨 員/(Staf (村益衝突審議小組審 利益衝突審議小組審 配測利益衝突處置及 石 	侍人/研究人員 Co-I/Sub-I/ esearcher 人員/審查委	Statement of Disclosure of Significant Financial Interests and Non-financial Relationships 顯著財務利益暨非財務關係申報表
/非財務關係 PI/ R 利益衝突之評估 第朔 員/(Staf (N 有 利益衝突審議小組審 查 利益衝突審議小組審 查 // Conf Re Force 監測利益衝突處置及 利益 Conf	Co-I/Sub-I/ esearcher 人員/審查委	Significant Financial Interests and Non-financial Relationships 顯著財務利益暨非財務關係申報表
 利益衝突之評估 有 有 利益衝突審議小組審 利益衝突審議小組審 近 紅益衝突處置及 利益 	人員/審查委	顯著財務利益暨非財務關係申報表
 利益衝突之評估 有 有 利益衝突審議小組審 利益衝突審議小組審 乙 石 利益衝突處置及 利益 日 月/(Staf (N A A		
 有 利益衝突審議小組審 ● <l< td=""><td>副)主任委員</td><td>Statement of Disclosure of</td></l<>	副)主任委員	Statement of Disclosure of
 利益衝突審議小組審 1 利益衝突審議小組審 査 Conf Re Forc 利益 近 二 監測利益衝突處置及 二 	耐圧性要員 /Reviewers/ ice) Chair	Non-financial Relationships
利益衝突審議小組審 查 Forc 私益 監測利益衝突處置及 Conf	暫突審議小 組	相關送審文件/顯著財務利益暨非財
查	審查委員	務關係申報表 , Relevant Submission Documents/
E E 別利益衝突處置及 Conf	ict of Interes	Statement of Disclosure of
監測利益衝突處置及 Conf	eview Task e/Reviewers	Significant Financial Interests and Non-financial Relationships
	暫突審議小 組	
	ict of Interes	
	eview Task Force	Annual report during the execution of the Study
		山明兴帝子从/历站吐杏孔之两儿口
紀錄保存		
		相關送審文件/顯著財務利益暨非財 務關係申報表
	承辦人員	相關达番文件/顯者財務利益暨非財務關係申報表 務關係申報表 Relevant Submission Documents/
	承辨人員 Staff	務關係申報表 Relevant Submission Documents/ Statement of Disclosure of
		務關係申報表 Relevant Submission Documents/



- 5.2 申報顯著之財務利益/非財務關係
- 5.2 Disclosure of Significant Financial Interests/Non-financial Relationships
 - 5.2.1 計畫主持人於提出研究計畫送審時,每位研究人員(包含計畫 主持人/共同主持人/協同主持人/研究人員)均應申報是否持 有與臨床研究計畫相關之顯著財務利益以及可能構成利益 衝突之非財務關係:

業民總醫院 3 08 ⁻

- 5.2.1 With the principal investigator's submission of a study protocol, each research team member (including the principal investigator, co-investigator, sub-investigator, and researchers) shall submit a statement of disclosure of significant financial interests and other non-financial relationships that may cause conflict of interests related to the study protocol.
 - 5.2.1.1 填寫「顯著財務利益暨非財務關係申報表」以供人體研 究倫理審查委員會(以下簡稱本會)審查。
 - 5.2.1.1 Each research team member shall complete the "Statement of Disclosure of Significant Financial Interests and Non-financial Relationships" and submit it to the Institutional Review Board (IRB) for review.
 - 5.2.1.2 若申報內容有顯著財務利益時,則需另行填寫「顯著財務利益/非財務關係評估暨處置計畫說明表」。
 - 5.2.1.2 If any significant financial interest is stated in the "Statement of Disclosure of Significant Financial Interests and Non-financial Relationships," another form of the "Assessment and Plan of Handling Significant Financial Interests and Non-financial Relationships" shall be completed and submitted.
 - 5.2.1.3 若有財務利益狀況/非財務關係之改變時(自新取得財務 利益之日起回溯 12 個月之財務利益總和達顯著利益 門檻、或新增研究人員等)應於 30 日內更新申報資料。
 - 5.2.1.3 In the event of a change in the financial

A Commenter of the comm	臺中 References References	榮民總 g Veterans General H	•		
文件編號 IRB-本會-工作常 Document Number IRB-Regulations of Ope	規-2026 文件 臨)	末研究利益衝突審議及處置行 SOP for Handling Conf Interest in Clinical St	flict of tudy	頁次 Page 版次 Version	9/18 D版
fin sig da	ancial benefits mificant intere y of acquiring	ncial relationship (th over the last 12 mo st threshold calculati new financial benefit tc), the related repor	nths rea ing from ts or the	ches th the fir additic	ne st on

5.2.2 下列各款不屬於前條所稱財務利益:

5.2.2 The following circumstances do not constitute the financial interest referred to in the preceding paragraph:


should be updated and sent to the IRB within 30 days.

民總醫院


8.08.1

- 5.2.2.1 由臨床試驗/研究委託者支付給本院,再經由本院發給個人,因執行試驗/研究所需,且試驗/研究合約所明訂之合 理費用。
- 5.2.2.1 The amount of reasonable expenses needed for the implementation of the study paid by the sponsor to TCVGH and then by TCVGH to individuals involved in the study.
- 5.2.2.2 持有共同基金。
- 5.2.2.2 Mutual fund holdings
- 5.2.2.3 參加公立或非營利機構所舉辦之學術活動、委員會、專家小組或類似會議,且與該試驗/研究計畫不相關,所獲得之演講費、鐘點費、出席費、服務收入或類似費用。
- 5.2.2.3 Honoraria for speakers, hourly wages, attendance fees, service revenue or similar expenses for participating in academic activities, committees, expert groups or other similar meetings organized by public or non-profit organizations and unrelated to the study.
- 5.2.3 可能構成利益衝突之非財務關係,指下列任一:
- 5.2.3 The non-financial relationship, which might constitute a conflict of interest, shall refer to any of the following circumstances:
 - 5.2.3.1 臨床試驗/研究人員或其配偶擔任本計畫之試驗/研究委 託者及其相關實體之不支酬主管職或顧問。

Taichurd (8)	ia i	臺 Taichu							院 pital			
, IRB-本會-工作 IRB-Regulations of (文件 名稱 Title		研究利 SOP fo Inter	or Ha	ndlin	g Co	nflict	t of	Fage 版次	10/18 D版	-
	Any rese on-payi ponsor	earch ng po	sitic	m me on of	mbe supe	r or ervis	his/h	ner s	pous		a	-
5.2.3.2 オ 실	本臨床試 生做為試				/研究	已人員	員的」	直屬音	鄂屬、	助理或	學	
5.2.3.2 T a	he subj ssistant				-						es,	^{臺中榮6} 2023. <i>桑老</i>
	主持人(色 計畫書時 款之財務	序,應申	報	是否。	本院当	對該						
	princi nvestiga ving fina	ipal ator) s	ir hall	nvesti I decl	gato are i	r f TC	(co- VGł	inve ⊣ ho	stiga Ids a	tor ny of tl	or he	
5.2.4.1 x	本院為言 く。	亥臨床	試馬	歲/研究	究所亻	吏用.	之專	利或	著作	之所有	權	
5.2.4.1 T s	CVGH tudy.	is the	ow	ner o	f the	pate	ent c	or wo	ork us	ed in tl	he	
5.2.4.2 才 存	本院對該 肯智慧財								作或	技術,	獲	
	FCVGH rom trai echnolog	nsfer	of	techr	olog	y fo		-				
	 に 醫療 、 、 、 、 、 、 、 、 、 、 、 、 、	(研究	計	畫所係	も用⇒							
tł	The cha Idministi ne pater cense fe	rative	or	resea	rch o	depa	rtme	ent is	s the	owner	of	



- 5.2.5.4 不須揭露之贊助機構:政府機關、大學或研究所等高等 教育機構及其隸屬研究單位、教學醫院及醫學中心。
- 5.2.5.4 The following sponsors do not need to be disclosed: Governmental organizations, higher education institutions such as universities or graduate institutes



and their affiliated research units, teaching hospitals and medical centers.

民總醫

.08.1


5.3 利益衝突之評估


- 5.3 Conflict of Interest Assessment
 - 5.3.1 IRB 下設有利益衝突審議小組,就潛在之利益衝突案件進行 審查,並提供減免、迴避利益衝突之處置建議。小組召集人 為主任委員,小組成員 4-6 位以機構外委員為原則,由小組 召集人邀請擔任。
 - 5.3.1 A "Conflict of Interest Review Task Force" is set up under supervision of the IRB to review potential conflict of interest cases and to give suggestions regarding handling, reducing, and avoiding conflicts of interest. The IRB Chair serves as the Coordinator of the Conflict of Interest Review Task Force and invites 4 to 6 non-TCVGH-affiliated members to serve in the Task Force.
 - 5.3.2 IRB 受理申報文件,確認每一臨床試驗/研究計畫是否有個人 或機構的顯著財務利益。若有顯著財務利益或可能構成利益 衝突之非財務關係之案件,將送請利益衝突審議小組審查。
 - 5.3.2 Upon receipt of a statement of disclosure, the IRB shall verify if any personal or institutional significant financial interest is involved in the study. If any significant financial interest is involved in the study, or if any non-financial relationship may constitute conflict of interest, the case shall be submitted to the Conflict of Interest Review Task Force for review.
- 5.4 利益衝突審議小組審查
- 5.4 The Review and Suggestions by the Conflict of Interest Review Task Force
 - 5.4.1 利益衝突審議小組委派一位小組審查委員進行審查,審查結 束後將審查意見通知計畫主持人。
 - 5.4.1 The Conflict of Interest Review Task Force shall assign a member from the Task Force to review each conflict of

	Taiching to be a server the server to be a server t	-	榮 民 g Veterans				
. –	IRB-本會-工作常規-2026 IRB-Regulations of Operation-2026		末研究利益衝突 SOP for Han Interest in	dling Co	onflict of	頁次 Page 版次 Version	13/18 D版
		shall be i 為「推薦 將小組》	informed of	the revi 查意見損 書處行政	ew comm 交予利益 人員,排	ents. 衝突審	議
	Review The Task discusse	will be Task Fo Force v d in th	is "Recomr submitted to rce for revi vill give the ne latest l er it can be a	o the ew of o respons IRB fu	Conflict of conflict of se to the s Il board	f Intere interes taff to b	est st. De
		人補件	§正」,則將等 (回覆審查意 回避、減免者	愈見)天	數為7個	日曆天	, 202

說明是否依建議迴避、減免或撤除潛在的利益衝突。計 畫主持人之回覆意見提交予利益衝突審議小組審閱後, 將小組決議交付秘書處行政人員,排入最近一次 IRB 大 會審查,以決定是否通過。

- 5.4.1.2 If the result is "Modifications required as suggested, "the suggestions will be sent to the principal investigator, the PI should respond within 7 calendar days to the Task Force whether he will avoid, reduce or remove the potential conflict of interest according to the suggestions. The Task Force will give the response to the staff to be discussed in the latest IRB full board meeting regarding whether it can be approved or not.
- 5.4.2 利益衝突審議小組依據以下考量,決議是否有利益衝突,並 做相關處置建議並提報人體研究倫理審查委員會,包括:
- 5.4.2 The Conflict of Interest Review Task Force convenes to deliberate on a potential conflict of interest case, make resolutions, give suggestions and report to the IRB regarding the following issues:
 - 5.4.2.1 臨床試驗/研究的學術價值。








interest.

- 5.4.4 人體研究倫理審查委員會參考利益衝突審議小組之建議,決定是否通過試驗/研究計畫或核准試驗/研究計畫繼續執行,並確認是否符合試驗/研究委託機構以及主管機關的通報規定。
- 5.4.4 Based on the <u>suggestion</u> made by the Conflict of Interest Review Task Force, the IRB decides whether to pass the trial/study protocol or approve trial/study protocol to be continued, and verify whether it complies with the reporting requirements defined by the sponsor and competent authority.

臺中榮<mark>民總醫院</mark>)23.08.1(

- 5.5 監測利益衝突處置及違規處置(COI monitoring)
- 5.5 Conflict of Interest (COI) Monitoring
 - 5.5.1 落實監測機制,以及顯著財務利益衝突違規之處置。
 - 5.5.1 The purpose of COI Monitoring is to implement the monitoring mechanism to handle cases of conflict of significant financial interest.
 - 5.5.2利益衝突審議小組審查涉及利益衝突的人員計畫執行期間之 年度報告,確認是否確實遵循利益衝突處置建議,迴避或減 免利益衝突。
 - 5.5.2 The Conflict of Interest Review Task Force shall review the annual report submitted by the personnel with a conflict of interest in the course of the study and confirm if suggestions made by the Task Force have been followed to avoid or reduce the conflict of interest.
 - 5.5.3利益衝突審議小組將不定期稽核主持人是否確實遵循利益衝 突處置建議,迴避或減免利益衝突,並將結果陳報本會。
 - 5.5.3 The Conflict of Interest Review Task Force shall conduct an audit periodically to verify if the principal investigator has followed the suggestions made by the Conflict of Interest Review Task Force to avoid or reduce a conflict of interest; the result of the audit shall be reported to the IRB



	R R R R R R R R R R R R R R R R R R R	-	中 榮 ung Vetera					
	會-工作常規-2026 tions of Operation-2026	文件 名稱 Title		Hand	≶議及處置 ling Con Clinical S	flict of	頁次 Page 版次 Version	18/18 D版
<u>Cent</u> <u>IRB.</u> 5. <u>7</u> 紀錄 5. <u>7</u> Reco 相關 Rele	uate the a mation prov er, and if the 保存(Record ords Retentio 人員應依據 vant person uidelines be	<u>vided</u> ere is I Keep on 如下規 nel sh	<u>a conflict (</u> ping) 。定,妥善(<u>Huma</u> of inte	an Rese erest, it v -項紀錄	<u>earch F</u> <u>vill be re</u> °	ported	<u>on</u> to
編號 Document Number	紀	錄名和 e of Docum	•		存地點 ion Location		序期限 on Period	
1	顯著財務利益 表 (與 PTMS Statement of Significant Fin and Non-finan (same as the	表格一 Disclos nancial ncial Re	致) sure of Interests elationships		辦公室 Office	結束後1	:/研究計畫 5 年 fter the stud	

	(same as the form on PTMS)	
2	利益衝突審查決議文件 Documents on the Resolution of Conflict of Interest Cases	IRB 辨公室 IRB Office
财化		

6.附件 無。

6. Appendix None.

榮民總醫院 3.08.10

臨床試驗/研究計畫

15 years after the study

結束後 15 年